The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life sciences clusters. Yet that has not stopped several other regions from trying to carve out their own piece of the life science pie. Recently the commercial real estate firm Jones Lang LaSalle identified nine emerging regions: Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis. While the first three are pretty established, a stronger case can be made for the rest as emerging clusters. As active as all have been, however, they remain overshadowed by San Francisco Bay Area as well as Boston and Cambridge. Do you think any of the newly identified regions will outpace its established rivals?
How much do you foresee emerging bioclusters growing in 2012?
A Great Deal